论文部分内容阅读
目的应用辛伐他汀治疗高脂血症合并非酒精性脂肪性肝病(NAFLD),观察载脂蛋白B(Apo-B)与高脂血症合并非酒精性脂肪性肝病之间的关系。判断Apo-B能否作为临床诊断高脂血症合并NAFLD的一个参考指标。方法应用辛伐他汀口服及生活饮食干预等综合疗法,对183例高脂血症合并非酒精性脂肪性肝病患者进行治疗,观察治疗前后Apo-B水平,肝功能,肝脏B超或CT等变化情况。结果 Apo-B随总胆固醇,甘油三脂等的好转而逐渐好转,其中53例在总胆固醇,甘油三酯等完全正常后,Apo-B才最后正常。血脂各项的好转,肝功能,肝脏B超等均有改善。结论 Apo-B在高脂血症合并NAFLD的发生发展中有一定的血清学改变的基础。Apo-B可考虑作为高脂血症合并NAFLD的诊断综合参考指标之一,降脂治疗对高脂血症合并NAFLD有一定的改善作用。
Objective To investigate the relationship between apolipoprotein B (Apo-B) and hyperlipidemia and non-alcoholic fatty liver disease (OSA) in patients with hyperlipidemia and nonalcoholic fatty liver disease (NAFLD). To determine whether Apo-B can be used as a reference for clinical diagnosis of hyperlipidemia complicated with NAFLD. Methods A total of 183 patients with hyperlipidemia and non-alcoholic fatty liver disease were treated with the combination of simvastatin, oral and dietary interventions. The levels of Apo-B, liver function, B-ultrasound and CT in the liver were observed before and after treatment Happening. Results Apo-B gradually improved with the improvement of total cholesterol and triglyceride. Among 53 cases, Apo-B was the last normal after total cholesterol and triglyceride were completely normal. Improvement of blood lipids, liver function, liver B ultrasound have improved. Conclusion Apo-B has some serological changes in the development of NAFLD with hyperlipidemia. Apo-B can be considered as a diagnostic reference marker for the diagnosis of hyperlipidemia combined with NAFLD, lipid-lowering therapy on hyperlipidemia with NAFLD have some improvement.